UnitedHealth selloff after DOJ fraud probe ‘perhaps overly harsh,’ says Leerink
Leerink reiterates an Outperform rating and $675 price target on shares of UnitedHealth (UNH). The Wall Street Journal reported that the ...
Leerink sees potential for ‘reset’ in Hims & Hers with Ozempic shortage ended
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
Lantheus to Present at Upcoming Investor Conferences
Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient ...
Leerink Partnrs Has Bullish Estimate for NBIX Q1 Earnings
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now ...
What is Leerink Partnrs’ Estimate for Lantheus Q1 Earnings?
Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz forecasts that the ...